



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

 Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: August 22, 2007 (use as many sheets as necessary)		Complete if Known	
		Application Number	10/674,065
		Filing Date	9/30/2003
		First Named Inventor	A. Robin Poole
		Art Unit	1652
		Examiner Name	Hope A. Robinson
		Attorney Docket Number	079328-0105
Sheet	1	of	1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code* Number* Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ⁶
HHP	B1	BORDO et al., "Suggestions for 'Safe' Residue Substitutions in Site-directed Mutagenesis," J. Mol. Biol., 1991, 217:721-729.			
	B2	DATABASE UniProt [Online] 21 July 1986, "Collagen alpha-1(II) chain precursor (Alpha-1 type II collagen) (Fragments)." XP002438406 retrieved from EBI accession no. UNIPROT:P02459 Database accession no. P02459, abstract (3 pages).			
	B3	DATABASE Geneseq [Online] 6 August 2001, "Human alpha1 (I) type I collagen helical domain (residues 179-280)." XP002438407 retrieved from EBI accession no. GSP:AAE02701 Database accession no. AAE02701, abstract (1 page).			
	B4	DATABASE Geneseq [Online] 7 September 2001, "Synthetic human target autoantigen shCollagen/RA." XP002440590 retrieved from EBI accession no. GSP:AAU02072 Database accession no.: AAU02072, abstract (1 page). Ben-Nun et al.			
	B5	TAYLOR et al., "The Classification of Amino Acid Conservation," J. Theor. Biol., 1986, 119:205-218.			
	B6	YASUDA et al., "A Fibronectin Fragment Induces Type II Collagen Degradation by Collagenase Through an Interleukin-1-Mediated Pathway," Arthritis & Rheumatism, January 2002, 46(1):138-148.			
✓	B7	YASUDA et al., "Peptides of type II collagen can induce the cleavage of type II collagen and aggrecan in articular cartilage," Matrix Biology, September 2006, 25(7):419-429.			

Examiner Signature		Date Considered	9/30/07
--------------------	---	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.